Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

St. Jude Expects Epic HF CRT Approval By May 2004 NASPE/HRS Meeting

This article was originally published in The Gray Sheet

Executive Summary

St. Jude Medical is lowering average selling prices for its U.S. ICDs and pacemakers by roughly 5% to counter Guidant and Medtronic's strategy of "bundling" cardiac resynchronization therapy defibrillators (CRT-D) with traditional ICDs and pacemakers

You may also be interested in...



St. Jude ICD, Tissue Valve Differentiation Will Fall To Incoming CEO Starks

Incoming Chairman and CEO Daniel Starks will direct St. Jude Medical's efforts to catch up with established players in the tissue valve and cardiac resynchronization therapy defibrillator markets

St. Jude ICD, Tissue Valve Differentiation Will Fall To Incoming CEO Starks

Incoming Chairman and CEO Daniel Starks will direct St. Jude Medical's efforts to catch up with established players in the tissue valve and cardiac resynchronization therapy defibrillator markets

St. Jude’s RHYTHM

Heart failure ICD resynchronization treatment data filing is slated for the week of Dec. 15. St. Jude expects the modular PMA submission, including the Epic HF and Atlas+ HF ICDs, Aescula 1055K and Quicksite 1056K left heart leads, will lead to approval by May 2004 (1"The Gray Sheet" Oct. 20, 2003, p. 22). Minimum enrollments for the Quicksite phase of the RHYTHM study were completed in Q3, but follow-up will wrap up the week of Dec. 1...

Related Content

UsernamePublicRestriction

Register

LL1132440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel